Briefing
Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.
ASCO 2025 abstract 5502 of the CALLA NeXT Personal analysis: baseline ctDNA detection 99%; 6-month detection 23% with durvalumab+CRT vs 36% with CRT; baseline median ctDNA 5,268.2 ppm; PFS HRs for low vs high baseline ctDNA 0.57 (0.26–1.26) with D+CRT and 0.62 (0.31–1.23) with CRT.
- n: Biomarker-evaluable population 185 / 186 / 130 at baseline (C1D1) / C3D1 / 6 months; parent trial 770 randomized
- Assay: NeXT Personal (Personalis), ultrasensitive tumor-informed MRD assay with up to 1,800 patient-specific variants from WGS